T cells lead the charge against solid tumors
IF 23.5
1区 医学
Q1 ONCOLOGY
引用次数: 0
Abstract
In 2024, two groundbreaking approvals from the US Food and Drug Administration for T cell-based therapies that target solid tumors were achieved. Lifileucel, a polyclonal tumor-infiltrating lymphocyte-based product for melanoma, and afamitresgene autoleucel, a gene-engineered T cell receptor product for sarcoma, mark a major shift from the six chimeric antigen receptor T cell therapies previously approved for hematological malignancies.
T 细胞是抗击实体瘤的主力军。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
Nature cancer
Medicine-Oncology
CiteScore
31.10
自引率
1.80%
发文量
129
期刊介绍：
Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates.
Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale.
In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
